Global Inhaled Nitric Oxide Market Insights and Forecast to 2028

Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).

Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
Market Analysis and Insights: Global Inhaled Nitric Oxide Market
Due to the COVID-19 pandemic, the global Inhaled Nitric Oxide market size is estimated to be worth US$ 1181.6 million in 2022 and is forecast to a readjusted size of US$ 1906.6 million by 2028 with a CAGR of 8.3% during the review period. Fully considering the economic change by this health crisis, 800 ppm accounting for % of the Inhaled Nitric Oxide global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Near-term and Pre-term Infants PPHN segment is altered to an % CAGR throughout this forecast period.
Mallinckrodt monopolizes the global Inhaled Nitric Oxide market, holding a share about 65%.
North America is the largest market, with a share about 77%, followed by Asia-Pacific and Europe, have a share about 20 percent.
In terms of product, 800 ppm is the largest segment, with a share over 50%. And in terms of application, the largest application is Near-term and Pre-term Infants PPHN, followed by Children and Adult ARDS, etc.
Global Inhaled Nitric Oxide Scope and Segment
Inhaled Nitric Oxide market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Inhaled Nitric Oxide market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
800 ppm
100 ppm
Others
Segment by Application
Near-term and Pre-term Infants PPHN
Children and Adult ARDS
Other Diseases
By Company
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Frequently Asked Questions